Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Fig. 1

Flow diagram demonstrating methods for identification of studies to assess the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events(SSEs) as the primary end point in postmenopausal women with oestrogen-receptor-positive advanced breast cancer

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us